Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
Public ClinicalTrials.gov record NCT02180217. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study aimed to confirm long-term efficacy and safety of LCI699 for the treatment of patients with Cushing's disease. It was a pivotal trial which supported the registration of LCI699 for the treatment of patients with Cushing's disease in the US and the EU. This is a phase lll, multi-center, double-blind, randomized withdrawal study of LCI699 following a 24 week, single-arm, open-label dose titration and treatment period which evaluated the safety and efficacy of LCI699 for the treatment of patients with Cushing's disease.
Study identification
- NCT ID
- NCT02180217
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 137 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 6, 2014 (Actual)
- Primary completion
- Feb 21, 2018 (Actual)
- Completion
- Dec 4, 2019 (Actual)
- Last update posted
- Jan 6, 2021
2014 – 2019
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Colorado Hospital SC - LCI699C2301 | Aurora | Colorado | 80045 | — |
| Emory University School of Medicine G2304 - C2301 | Atlanta | Georgia | 30322 | — |
| Northwestern University SC - LCI699C2301 | Chicago | Illinois | 60611 | — |
| The Johns Hopkins University School of Medicine Johns Hopkins University | Baltimore | Maryland | 21205 | — |
| Massachusetts General Hospital Neuroendocrine Unit | Boston | Massachusetts | 02114 | — |
| University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | 48109 | — |
| Mount Sinai School of Medicine SC - LCI699C2301 | New York | New York | 10029 | — |
| Columbia University Medical Center New York Presbyterian SC - LCI699C2301 | New York | New York | 10032 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Oregon Health and Science University SC LCI699C2301 | Portland | Oregon | 97239 | — |
| University of Pennsylvania Clinical Studies Unit Unniv SC | Philadelphia | Pennsylvania | 19104 | — |
| Medical College of Wisconsin MCW 2 | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 48 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02180217, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 6, 2021 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02180217 live on ClinicalTrials.gov.